Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are currently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $25.50.
Several equities research analysts have recently commented on NVCR shares. Wedbush reaffirmed an “outperform” rating and set a $24.00 price target on shares of NovoCure in a research report on Thursday, July 25th. Wells Fargo & Company reduced their target price on shares of NovoCure from $42.00 to $40.00 and set an “overweight” rating for the company in a report on Friday, July 26th. HC Wainwright lifted their price target on shares of NovoCure from $22.00 to $24.00 and gave the stock a “neutral” rating in a research note on Friday, July 26th. Finally, Evercore ISI boosted their price objective on shares of NovoCure from $14.50 to $20.00 and gave the company an “in-line” rating in a research report on Tuesday, July 2nd.
View Our Latest Research Report on NovoCure
Hedge Funds Weigh In On NovoCure
NovoCure Trading Down 1.6 %
NASDAQ:NVCR opened at $19.44 on Monday. The company has a 50 day simple moving average of $18.55 and a two-hundred day simple moving average of $17.42. The company has a market cap of $2.10 billion, a PE ratio of -10.74 and a beta of 0.70. The company has a current ratio of 6.46, a quick ratio of 6.22 and a debt-to-equity ratio of 1.81. NovoCure has a 12 month low of $10.87 and a 12 month high of $24.74.
NovoCure (NASDAQ:NVCR – Get Free Report) last posted its quarterly earnings data on Thursday, July 25th. The medical equipment provider reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.09. The company had revenue of $150.40 million during the quarter, compared to analysts’ expectations of $135.83 million. NovoCure had a negative return on equity of 45.68% and a negative net margin of 30.67%. NovoCure’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.54) earnings per share. Research analysts forecast that NovoCure will post -1.34 earnings per share for the current year.
About NovoCure
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.
Featured Stories
- Five stocks we like better than NovoCure
- Financial Services Stocks Investing
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- What is the S&P 500 and How It is Distinct from Other Indexes
- MarketBeat Week in Review – 8/26 – 8/30
Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.